Resective Surgery versus Debridement in Stage 2 Medication-Related Osteonecrosis of the Jaw
Source abstract
Abstract
The aim of this study is to analyze surgical and functional outcomes in order to verify the applicability of surgical treatment guidelines as foreseen by MASCC/ISOO/ASCO 2019. Patients affected by stage 2 MRONJ refractory to conservative management were grouped if underwent surgical resection (Group A) or debridement (Group B). Health-related quality of life was evaluated by using the European Organization for Research and Treatment of Cancer questionnaires, QLQ-C30 and H&N35. Statistical analysis was performed using Wilcoxon/Mann–Whitney test, Kaplan–Meier test, Cox regression model and Cox multivariate regression. Group A showed higher complete healing cases vs. group B. Recurrence rate difference in group A vs. group B was statistically significant. Debridement is an unfavorable prognostic factor when compared to surgical resection (p = 0.0032, HR 4.9). Quality of life mean values showed a marked improvement in Group A and a slight improvement in Group B. Debridement has 4.9 times more risk to develop recurrence when compared to surgical resection. A more satisfactory quality of life was shown in patients subject to resective surgery with an improving trend from baseline. Debridement patients showed more variability of results and an overall negative trend at the end of the 6-month follow-up.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone health and treatments · Bone and Joint Diseases · Cancer Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Oral and Maxillofacial Surgery Unit, Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania “Luigi Vanvitelli”, Via Luigi De Crecchio, 6, 80138 Naples, Italy
Maxillofacial Surgery Unit, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, Via Pansini, 5, 80131 Naples, Italy
References (66)
Show source-provided references
1. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update10.1016/j.joms.2014.04.031 ↗
2. Campisi, G., Mauceri, R., Bertoldo, F., Bettini, G., Biasotto, M., Colella, G., Consolo, U., Di Fede, O., Favia, G., and Fusco, V. (2020). Medication-Related Osteonecrosis of Jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020. Int. J. Environ. Res. Public Health, 17.10.3390/ijerph17165998 ↗
3. Bisphosphanates and oral cavity avascular bone necrosis10.1200/JCO.2003.99.132 ↗
4. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases10.1016/j.joms.2004.02.004 ↗
5. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents10.1080/07357900802208608 ↗
6. Erratum to: Safety of long-term denosumab therapy: Results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer10.1007/s00520-015-2985-1 ↗
7. Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer10.1007/s10549-010-0866-3 ↗
8. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials10.1007/s10147-013-0561-6 ↗
9. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials10.1111/clr.12556 ↗
10. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: A meta-analysis10.1007/s10549-009-0432-z ↗
11. Osteonecrosis of the Jaw in the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS)10.1002/jbmr.2693 ↗
12. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors10.1200/JCO.2005.04.2465 ↗
13. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates10.1359/jbmr.080205 ↗
14. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates10.1097/COC.0b013e3182155fcb ↗
15. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment10.1016/j.joms.2005.07.010 ↗
16. Surface-associated protein from Staphylococcus aureus stimulates osteoclastogenesis: Possible role in S. aureus-induced bone pathology10.1093/rheumatology/37.10.1095 ↗
17. Bacterially induced bone destruction: Mechanisms and misconceptions10.1128/iai.64.7.2371-2380.1996 ↗
18. Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?10.1016/j.bone.2009.07.011 ↗
19. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline10.1200/JCO.19.01186 ↗
20. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy10.14219/jada.archive.2009.0049 ↗
21. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw
22. Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris10.1016/j.ijom.2010.11.006 ↗
23. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw10.1016/j.tripleo.2010.04.015 ↗
24. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology10.1093/jnci/85.5.365 ↗
25. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group10.1016/S0959-8049(00)00186-6 ↗
26. Fayers, P.M., Aaronson, N.K., Bjordal, K., Groenvold, M., Curran, D., and Bottomley, A. (2001). The EORTC QLQ-C30 Scoring Manual, European Organization for Research and Treatment of Cancer. [3rd ed.].
27. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic10.1016/S0278-2391(03)00720-1 ↗
28. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy10.1002/cncr.21130 ↗
29. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)10.1016/j.oraloncology.2014.08.016 ↗
30. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: Review of 33 surgical cases10.1016/j.joms.2008.12.057 ↗
31. Evaluation of the treatment strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis10.1002/jbmr.3191 ↗
32. Bisphosphonate-related osteonecrosis of the jaws: A comprehensive review10.1111/j.1600-0714.2007.00540.x ↗
33. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review10.1016/j.tripleo.2005.10.045 ↗
34. Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: A comparative study focused on multiple myeloma10.1111/j.1365-2257.2006.00841.x ↗
35. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: A prospective study10.1016/j.tripleo.2010.02.020 ↗
36. Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw10.1016/j.joms.2015.09.024 ↗
37. Painful trigeminal neuropathy induced by oral bisphosphonate-related osteonecrosis of the jaw: A new etiology for the numb-chin syndrome
38. The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw10.1016/j.joms.2008.09.028 ↗
39. Preventive protocol for tooth extractions in patients treated with zoledronate: A case series10.1016/j.joms.2010.10.055 ↗
40. Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study10.1007/s00784-013-0979-2 ↗
41. Treatment of bisphosphonate-related osteonecrosis of the jaws: Presentation of a protocol and an observational longitudinal study of an Italian series of cases10.1016/j.bjoms.2011.08.004 ↗
42. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: A Belgian case series10.1002/lary.20076 ↗
43. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome10.1093/annonc/mdn630 ↗
44. Bisphosphonate-related osteonecrosis of the jaw: Position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons10.1007/s00774-010-0162-7 ↗
45. A review of pharmaceutical agents and oral bone health: How osteonecrosis of the jaw has affected the field10.11607/jomi.te41 ↗
46. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws10.1007/s00432-010-0953-1 ↗
47. Osteonecrosis of the jaw: Dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab10.1016/j.clbc.2011.02.001 ↗
48. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience10.1093/annonc/mdr039 ↗
49. Lo Giudice, R., Puleio, F., Rizzo, D., Alibrandi, A., Lo Giudice, G., Centofanti, A., Fiorillo, L., Di Mauro, D., and Nicita, F. (2019). Comparative investigation of cutting devices on bone blocks: An SEM morphological analysis. Appl. Sci., 9.10.3390/app9020351 ↗
50. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws10.1016/j.joms.2009.01.006 ↗
51. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: First clinical results of a prospective pilot study10.1016/j.joms.2010.07.014 ↗
52. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: Six-year experience of a single institution10.1016/j.joms.2015.01.008 ↗
53. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: A prospective clinical study with 12 months follow-up10.1007/s00520-009-0688-1 ↗
54. Evaluation of the predisposing factors and involved outcome of surgical treatment in bisphosphonate-related osteonecrosis of the jaw cases including bone biopsies10.5125/jkaoms.2016.42.4.193 ↗
55. The saxon bisphosphonate register—Therapy and prevention of bisphosphonate-related osteonecrosis of the jaws10.1016/j.oraloncology.2011.11.004 ↗
56. Conservative surgical management of patients with bisphosphonate-related osteonecrosis of the jaws: A series of 120 patients10.1016/j.bjoms.2016.06.015 ↗
57. Bisphosphonates-related osteonecrosis of the jaws: A concise review of the literature and a report of a single-centre experience with 151 patients10.1111/j.1600-0714.2011.01091.x ↗
58. Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: A retrospective survey of 347 cases10.1016/j.joms.2012.05.019 ↗
59. Osteopathology of the jaw associated with bone resorption inhibitors: What have we learned in the last 8 years?
60. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study10.1016/j.oraloncology.2010.11.007 ↗
61. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus10.1002/jbmr.2405 ↗
62. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: A systematic review10.1016/j.ijom.2015.01.026 ↗
63. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws10.1016/j.jcms.2016.08.001 ↗
64. Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw10.5125/jkaoms.2018.44.4.174 ↗
65. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study10.1007/s00784-009-0293-1 ↗
66. De Cicco, D., Tartaro, G., Ciardiello, F., Fasano, M., Rauso, R., Fiore, F., Spuntarelli, C., Troiano, A., Lo Giudice, G., and Colella, G. (2021). Health-Related Quality of Life in Oral Cancer Patients: Scoping Review and Critical Appraisal of Investigated Determinants. Cancers, 13.10.3390/cancers13174398 ↗